vs
Barnes & Noble Education, Inc.（BNED）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Barnes & Noble Education, Inc.的1.3倍（$772.1M vs $598.2M），Revvity净利率更高（12.7% vs 4.2%，领先8.6%），Barnes & Noble Education, Inc.同比增速更快（6.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $61.9M），过去两年Barnes & Noble Education, Inc.的营收复合增速更高（20.0% vs 9.0%）
巴诺教育旗下的巴诺书店是美国门店数量最多的图书零售商，目前在美国各地经营着七百多家线下实体门店，是美国本土颇具影响力的线下图书零售企业，深耕图书零售领域多年。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BNED vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$598.2M
营收增速更快
BNED
高出1.0%
5.9%
净利率更高
RVTY
高出8.6%
4.2%
自由现金流更多
RVTY
多$99.9M
$61.9M
两年增速更快
BNED
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $598.2M | $772.1M |
| 净利润 | $25.0M | $98.4M |
| 毛利率 | 21.7% | — |
| 营业利润率 | 6.8% | 14.5% |
| 净利率 | 4.2% | 12.7% |
| 营收同比 | 6.9% | 5.9% |
| 净利润同比 | -49.7% | 3.9% |
| 每股收益（稀释后） | $0.72 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNEDRVTY
| Q4 25 | $598.2M | $772.1M | ||
| Q3 25 | $274.2M | $698.9M | ||
| Q2 25 | $233.0M | $720.3M | ||
| Q1 25 | $419.7M | $664.8M | ||
| Q4 24 | $559.7M | $729.4M | ||
| Q3 24 | $250.9M | $684.0M | ||
| Q2 24 | $192.7M | $691.7M | ||
| Q1 24 | $415.4M | $649.9M |
净利润BNEDRVTY
| Q4 25 | $25.0M | $98.4M | ||
| Q3 25 | $-18.3M | $46.7M | ||
| Q2 25 | $-23.0M | $53.9M | ||
| Q1 25 | $17.9M | $42.2M | ||
| Q4 24 | $43.2M | $94.6M | ||
| Q3 24 | $-103.9M | $94.4M | ||
| Q2 24 | $-41.9M | $55.4M | ||
| Q1 24 | $-9.3M | $26.0M |
毛利率BNEDRVTY
| Q4 25 | 21.7% | — | ||
| Q3 25 | 20.2% | 53.6% | ||
| Q2 25 | 30.3% | 54.5% | ||
| Q1 25 | 22.3% | 56.5% | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 17.9% | 56.3% | ||
| Q2 24 | 28.7% | 55.7% | ||
| Q1 24 | 24.2% | 54.6% |
营业利润率BNEDRVTY
| Q4 25 | 6.8% | 14.5% | ||
| Q3 25 | -8.4% | 11.7% | ||
| Q2 25 | -4.9% | 12.6% | ||
| Q1 25 | 4.5% | 10.9% | ||
| Q4 24 | 8.4% | 16.3% | ||
| Q3 24 | -15.4% | 14.3% | ||
| Q2 24 | -16.3% | 12.4% | ||
| Q1 24 | 0.4% | 6.8% |
净利率BNEDRVTY
| Q4 25 | 4.2% | 12.7% | ||
| Q3 25 | -6.7% | 6.7% | ||
| Q2 25 | -9.9% | 7.5% | ||
| Q1 25 | 4.3% | 6.4% | ||
| Q4 24 | 7.7% | 13.0% | ||
| Q3 24 | -41.4% | 13.8% | ||
| Q2 24 | -21.7% | 8.0% | ||
| Q1 24 | -2.2% | 4.0% |
每股收益（稀释后）BNEDRVTY
| Q4 25 | $0.72 | $0.86 | ||
| Q3 25 | $-0.54 | $0.40 | ||
| Q2 25 | $2.97 | $0.46 | ||
| Q1 25 | $0.59 | $0.35 | ||
| Q4 24 | $1.63 | $0.77 | ||
| Q3 24 | $-7.69 | $0.77 | ||
| Q2 24 | $-15.68 | $0.45 | ||
| Q1 24 | $-3.49 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.7M | $919.9M |
| 总债务越低越好 | $122.5M | — |
| 股东权益账面价值 | $283.2M | $7.3B |
| 总资产 | $1.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资BNEDRVTY
| Q4 25 | $11.7M | $919.9M | ||
| Q3 25 | $7.3M | $931.4M | ||
| Q2 25 | $9.1M | $991.8M | ||
| Q1 25 | $9.2M | $1.1B | ||
| Q4 24 | $11.6M | $1.2B | ||
| Q3 24 | $8.2M | $1.2B | ||
| Q2 24 | $10.5M | $2.0B | ||
| Q1 24 | $8.1M | $1.7B |
总债务BNEDRVTY
| Q4 25 | $122.5M | — | ||
| Q3 25 | $170.0M | — | ||
| Q2 25 | $103.1M | — | ||
| Q1 25 | $141.2M | — | ||
| Q4 24 | $177.6M | — | ||
| Q3 24 | $221.9M | — | ||
| Q2 24 | $196.3M | — | ||
| Q1 24 | $30.2M | — |
股东权益BNEDRVTY
| Q4 25 | $283.2M | $7.3B | ||
| Q3 25 | $256.5M | $7.4B | ||
| Q2 25 | $272.2M | $7.6B | ||
| Q1 25 | $292.9M | $7.6B | ||
| Q4 24 | $211.4M | $7.7B | ||
| Q3 24 | $149.8M | $7.9B | ||
| Q2 24 | $80.4M | $7.9B | ||
| Q1 24 | $121.5M | $7.8B |
总资产BNEDRVTY
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $950.8M | $12.1B | ||
| Q2 25 | $790.3M | $12.4B | ||
| Q1 25 | $1.1B | $12.4B | ||
| Q4 24 | $1.0B | $12.4B | ||
| Q3 24 | $973.2M | $12.8B | ||
| Q2 24 | $909.9M | $13.4B | ||
| Q1 24 | $1.2B | $13.4B |
负债/权益比BNEDRVTY
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 2.44× | — | ||
| Q1 24 | 0.25× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $61.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.4% | 21.0% |
| 资本支出强度资本支出/营收 | 0.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.65× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-4.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BNEDRVTY
| Q4 25 | $66.2M | $182.0M | ||
| Q3 25 | $-67.6M | $138.5M | ||
| Q2 25 | $52.6M | $134.3M | ||
| Q1 25 | $-41.9M | $128.2M | ||
| Q4 24 | $47.4M | $174.2M | ||
| Q3 24 | $-143.5M | $147.9M | ||
| Q2 24 | $81.7M | $158.6M | ||
| Q1 24 | $-35.8M | $147.6M |
自由现金流BNEDRVTY
| Q4 25 | $61.9M | $161.8M | ||
| Q3 25 | $-71.3M | $120.0M | ||
| Q2 25 | $49.5M | $115.5M | ||
| Q1 25 | $-44.7M | $112.2M | ||
| Q4 24 | $44.4M | $149.8M | ||
| Q3 24 | $-147.5M | $125.6M | ||
| Q2 24 | $79.1M | $136.6M | ||
| Q1 24 | $-39.0M | $129.7M |
自由现金流率BNEDRVTY
| Q4 25 | 10.4% | 21.0% | ||
| Q3 25 | -26.0% | 17.2% | ||
| Q2 25 | 21.3% | 16.0% | ||
| Q1 25 | -10.7% | 16.9% | ||
| Q4 24 | 7.9% | 20.5% | ||
| Q3 24 | -58.8% | 18.4% | ||
| Q2 24 | 41.1% | 19.7% | ||
| Q1 24 | -9.4% | 20.0% |
资本支出强度BNEDRVTY
| Q4 25 | 0.7% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 0.7% | 2.4% | ||
| Q4 24 | 0.5% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
现金转化率BNEDRVTY
| Q4 25 | 2.65× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -2.34× | 3.03× | ||
| Q4 24 | 1.10× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNED
| Course Materials Product | $459.3M | 77% |
| General Merchandise Product | $112.9M | 19% |
| Serviceand Other | $26.1M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
